Functional Food Application of Okara Protein Hydrolysate (OPH)- for Anti-exercise-fatigue

NCT05000918 | Completed

• 1 other identifier: CS2-20042
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to investigate the anti-exercise-fatigue effects of okara protein hydrolysate (OPH) in men

Conditions

Healthy

Outcome Measures

Primary Outcomes (1)

• Change the metabolic substances level after intervention

  Compare the difference of blood lactate, lactate dehydrogenase, and creatine kinase level after exercise between pre- and post-intervention

  8th day, 35th day

Secondary Outcomes (1)

• Change the exercise time after intervention

  8th day, 35th day

Study Arms (1)

OPH group

EXPERIMENTAL

Participants should eat a pack of OPH once a day for 28 days. The dosage of the OPH is 11.74 g/day.

Dietary Supplement: Okara protein hydrolysate (OPH)

Interventions

Okara protein hydrolysate (OPH) DIETARY_SUPPLEMENT

Okara protein hydrolysate (OPH) was a pack of dried beige powder. It can be stored at room temperature, but it must be exposed to direct sunlight.

OPH group

Eligibility Criteria

• Age: 20 Years - 40 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• The subject is a male and aged 20-40.
• The subject has a usual exercise habit (exercising 2 times or more per week) and did not participate in professional sports competitions or professional sports training during the study period.
• No smoking or drinking habits.
• No food allergies and the liver function is normal.
• No cardiovascular diseases or other chronic diseases, and no serious illnesses requiring hospitalization during the study period.
• The subject can understand the test process described in the consent form and the possible potential risks and benefits, and can sign the consent form.
• The subject can accept dietary control during the trial period.

You may not qualify if:

• Those who have taken nutritional supplements containing branched-chain amino acids.
• Those who cannot complete the endurance exercise ability test.
• Those who are diagnosed with kidney disease, heart disease, or cancer and are still under active treatment.
• Have used other drugs, whose pharmacological effects may affect fatigue.
• Subjects who have systemic infections and require systemic antibiotics.

Sponsors & Collaborators

• Chung Shan Medical University: lead
• National Taichung University of Education: collaborator

Study Sites (1)

Chung Shan Medical University

Taichung, South, 402, Taiwan

Location

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 27, 2021
• First Posted: August 11, 2021
• Study Start: July 17, 2020
• Primary Completion: August 23, 2020
• Study Completion: October 31, 2020
• Last Updated: August 11, 2021

Record last verified: 2021-08

Data Sharing

• IPD Sharing: Will not share

Locations

TW (1)